Vantage releases its half-year analysis of sector performance:
Pharma, Biotech and Medtech Half-Year Review 2018
LONDON & BOSTON & TOKYO–(BUSINESS WIRE)– The first half of 2018 has seen biopharma IPOs and venture financing
accelerate from the already-healthy levels witnessed in 2017. Deal
making has dimmed further, however, raising concern that overheated
valuations in certain pockets of the sector are putting off buyers.
Meanwhile, despite the US FDA being on track for another strong year of
approvals, several big biotech and pharma companies are under
considerable pressure to rebuild their pipelines and replace ageing
The situation is reversed somewhat in medtech, where life is harder for
young device makers: a worsening reimbursement climate has put off
investors and a wave of megamergers among big cap medtechs has shrunk
the pool of buyers.
These findings and more were released today as part of the Pharma,
Biotech and Medtech Half-year Review 2018 report by Vantage – formerly
EP Vantage – the editorial arm of commercial intelligence firm Evaluate.
“A very strong funding climate for young drug makers, coupled with a
co-operative US regulator, is creating a lot of excitement in the small
and mid-cap space in biopharma,” said Amy Brown, author of the pharma
and biotech section. “Larger drug makers are desperate for innovation,
however, which is becoming increasingly expensive to buy – a quandary
that should concern executives and investors as 2018 progresses.”
“Smaller medtech companies are having difficulty finding buyers thanks
to consolidation, and venture cash is also hard to come by,” said
Elizabeth Cairns, author of the medtech portion of the report.
“Mid-stage groups have no choice but to turn to the public markets for
growth capital, explaining the surge in IPOs.” Other key findings from
the first half of 2018 include:
The report published today offers analysis and expert commentary on M&A
deals, venture financing, initial public offerings and FDA approvals in
the pharma and medtech sectors during the first a half of 2018. The
report is based on EvaluatePharma® and EvaluateMedTech® data. Download
the full report at http://www.evaluate.com/thought-leadership/vantage/vantage-2018-half-year-review
Vantage, formerly known as EP Vantage, provides award-winning,
thought-provoking news and insights into current and future developments
in the industry, and is the only pharmaceutical news service underpinned
by Evaluate’s commercial intelligence. Visit http://www.evaluate.com/vantage
for free access to daily, data-driven news for pharma, biotech, and
On Twitter: @Vantageanalysis.
About Evaluate Ltd
Evaluate provides trusted commercial intelligence for the pharmaceutical
and medical device industries. Our EvaluatePharma® online subscription
service provides a seamless view of the past, present and future of the
global pharmaceutical market in a single, standardised platform.
Evaluate has been a trusted partner to industry-leading organisations
for over 20 years. For more information on how we give our clients the
time and understanding to drive better decisions, visit us at www.evaluate.com.
Source: Evaluate Ltd